Here's more bit's n pieces to read how 2019 will be the year THC...

Here's more bit's n pieces to read how 2019 will be the year THC Global rises above the "one of many MC companies" bracket & taken seriously by the investment & media mob.

All going to plan by mid-year we'll be in full swing & duly recognised & re-rated.

Bit to read from various websites.

THC (ASX:THC) is now only second to Cann Group (ASX:CAN) in terms of the number of licences and permits they have. Both are still waiting on manufacturing licences.
That’s because federal (and state) licences are only the first step.
Growers also need a permit which involves a facility inspection and specifies things like which strains a licence holder can grow and the number and weight of its plants.
The number of companies actually growing cannabis locally is small: the only other companies with permits are Cann Group, unlisted companies Little Green Pharma in West Australia and MediFarm.
The permits were issued to THC subsidiary Canndeo and cover high CBD strains at the Queensland growing and R&D facility.
THC is waiting on manufacturing licences for the above factory, and for a Gold Coast botanicals extraction plant it bought from Leo Pharma in April for $2.55m.
It has also leased a tea tree plantation from Eve Investments (ASX:EVE) in NSW which it wants to turn into a marijuana growing facility.


As per the ASX announcement dated 21st December 2018, the THC Global Group Limited (ASX: THC), formerly The Hydroponics Company Ltd, announces approval of two major cannabis permits by its wholly owned subsidiary Canndeo Limited. The receipt of grants from the Office of Drug Control (ODC), will allow the cultivation and production of the company’s proprietary high CBD strains at its Queensland Growing and R&D facility.
At the request of the company releasing major announcement, ASX placed the securities of THC Global Group Ltd on a trading halt effective 19th December 2018. The securities resumed trading today. The shares of the company rallied to 46.5 cents, up by 8.14% at the close of the trading session.
The company is expanding the cannabis plant supply for processing into cannabis oils and other medicinal cannabis drugs at its Australian manufacturing facility. The granting of these licenses complements THC Global’s farm-to-pharma medicinal cannabis strategy. Additionally, the company aims at maximizing yields and quality in its full-scale cultivation at Australian growing facilities. The company will be henceforth assisted by the data generated through the research under the permits.
THC Global Group is a biopharmaceutical company involved in providing medicinal cannabis products. THC has two high-grade medicinal cannabis growing sites based in Australia. One is “NSW Growing Site” with a large-scale capacity of up to 600k plants every year. The second is “Queensland Growing and R&D facility” capable of producing expected 850k strain clones per year
The company also operates a global hydroponics business, focusing on the manufacturing and distribution of hydroponics equipment, materials, and nutrients across North America, via Crystal Mountain Manufacturing (100% Owned by THC Limited). As announced on 28th November 2018, THC also expanded its reach across New Zealand medicinal cannabis market. This is an excellent step considering the recent proposal for cannabis legalization for New Zealand patients.
The THC Global has two additional manufacturing licence applications under review over two areas- ODC permitted growing and R&D facility, and its large-scale manufacturing facility.
The company is in a unique position with strong potential of establishing its mark as a leading cannabis producer. It has fully built production ready sites, submitted for licencing and permitting while some of its peer companies in the industry are struggling for the license in the pre-construction phase.
The company’s Global CEO, Ken Charteris commented stated that the company is looking forward to establishing itself as one of the only Australian companies to have production ready facilities with licencing and permitting at an advanced stage soon. The management is planning to partner with global commercial partners in further research and development activities on the proprietary strains.
---------------------

The latest news out of the company is that it has received permits for its growing Research and Development facility in Queensland.
In an important step for the company, THC Global announced today that the Office of Drug Control (ODC) had granted two Cannabis Permits to its wholly-owned subsidiary Canndeo, allowing for the cultivation and production of proprietary high CBD strains.
CBD, or cannabidiol, is a cannabinoid that does not have intoxicating effects. It is being studied for a variety of therapeutic effects and has shown promise in treatments for anxiety, insomnia, pain and paediatric epilepsy.
CEO Ken Charteris greeted the news positively, saying:
‘The receipt of these permits is a critical step in progressing our Australian farm-to-pharma strategy and confirms expectations that THC Global will be in a position to commence full-scale production in the near term as one of the only Australian companies to have production ready facilities with licensing and permitting at an advanced stage.’
What’s next for THC Global?
There are a number of things investors will be looking for from THC Global in the next two quarters.
In Q1 2019 THC Global plans to develop a medical trial and secure validation of its medicinal cannabis product from its manufacturing facility.
In Q2 2019 it will be seeking an offtake agreement for export as well as revenue generation from locally manufactured products.
The share price of a number of cannabis stocks on the ASX has suffered this year after an explosion of interest around January.
In recent news there has been a push for legalisation of cannabis in the ACT with backbencher Michael Petterson saying:
‘Cannabis legalisation is not a radical idea. There are now 10 states in the United States of America that have legalised cannabis along with Canada, South Africa and Uruguay.’
While legalisation may still be some way off, it is expected the Australian medical cannabis market may potentially be worth more than $1 billion by 2025.

-------------

The balance sheet of the company appears to be healthy as the company has maintained a strong net asset balance of $32,756,300 and a debt-equity ratio of 0.14. The company holds a strong position regarding the total current asset which $11,203,423 and total current liabilities of $3,886,575 which indicates that the company can efficiently manage its short-term obligations as well as its working capital requirements. However, during this period there is an increase in the accumulated losses of the company by $2,427,578 which could create a negative impact on the investors and the shareholders of the company. It also highlights the poor operating performance of the company. The total shareholder’s equity is worth $32,756,300.
The company used net cash of $3,325,055 in its operating activities where the primary source of cash outflow was in the form of payment to the suppliers and employees. The company used net cash of $2,928,188 in its investing activities where the primary source of cash outflow was in the form of payment for patents and the development costs. The company generated $3,804,291 through its financing activities where the primary source of cash inflow was in the form of the issue of shares.